AFT Pharmaceuticals has entered a licensing and development agreement for its Pascomer drug with US-based Timber Pharmaceuticals.
Pascomer treats facial angiofibromas, which are skin lesions associated with tuberous sclerosis, a skin condition. The company said the disease affects 30,000 people
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive FREE offer for uni students studying at a New Zealand university (valued at $499).
